The table below shows Travere Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
-
-
-
-
-
-
Cost of revenue
$10.34M
$7.74M
$11.45M
$4.42M
$3.82M
$6.13M
Gross profit
-
-
-
-
-
-
R&D
-
-
-
$7.50M
-
-
SG&A
$337.20M
TVTX annual revenue (10-K history)
Travere Therapeutics, Inc. reported annual revenue of $490.73M for fiscal year 2025. That is up 110.5% from $233.18M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $133.59M (FY 2016) to $490.73M. Figures come from the company's audited annual reports as filed with the SEC.